FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089367981> ?p ?o ?g. }

• W3089367981 endingPage "264" @default.
• W3089367981 startingPage "1" @default.
• W3089367981 abstract "Background Hepatocellular carcinoma is the most common type of primary liver cancer. Treatment choice is dependent on underlying liver dysfunction and cancer stage. Treatment options include conventional transarterial therapies for patients with intermediate-stage disease and systemic therapy [e.g. sorafenib (Nexavar ® ; Bayer plc, Leverkusen, Germany)] for patients with advanced-stage disease. Selective internal radiation therapies deliver radiation to liver tumours via microspheres that are injected into the hepatic artery. There are three selective internal radiation therapies: TheraSphere™ [BTG Ltd, London, UK (now Boston Scientific, Marlborough, MA, USA)], SIR-Spheres ® (Sirtex Medical Ltd, Woburn, MA, USA) and QuiremSpheres ® (Quirem Medical BV, Deventer, the Netherlands). Objective To assess the clinical effectiveness and cost-effectiveness of selective internal radiation therapies for treating patients with unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma. Methods A search was undertaken to identify clinical effectiveness literature relating to selective internal radiation therapies and relevant comparators for the treatment of hepatocellular carcinoma. Studies were critically appraised and summarised. The network of evidence was mapped to estimate the relative effectiveness of the different selective internal radiation therapies and comparator treatments. An economic analysis evaluated the cost-effectiveness. Results Twenty studies were included in the clinical effectiveness review. Two large randomised controlled trials rated as having a low risk of bias [SARAH: Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled Phase 3 trial. Lancet Oncol 2017; 18 :1624–36; and SIRveNIB: Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018; 36 :1913–21] found no significant difference in overall survival or progression-free survival between SIR-Spheres and sorafenib (systemic therapy) in an advanced population, despite greater tumour response in the SIR-Spheres arm of both trials. There were some concerns regarding generalisability of the SARAH and SIRveNIB trials to UK practice. All other studies of SIR-Spheres, TheraSphere or QuiremSpheres were either rated as being at a high risk of bias or caused some concerns regarding bias. A network meta-analysis was conducted in adults with unresectable hepatocellular carcinoma who had Child–Pugh class A liver cirrhosis and were ineligible for conventional transarterial therapies. The analysis included the SARAH and SIRveNIB trials as well as a trial comparing lenvatinib (Kisplyx ® ; Eisai Ltd, Tokyo, Japan) (systemic therapy) with sorafenib. There were no meaningful differences in overall survival between any of the treatments. The base-case economic analysis suggested that TheraSphere may be cost-saving relative to both SIR-Spheres and QuiremSpheres. However, incremental cost differences between TheraSphere and SIR-Spheres were small. In a fully incremental analysis, which included confidential Patient Access Scheme discounts, lenvatinib was the most cost-effective treatment and dominated all selective internal radiation therapies. In pairwise comparisons of sorafenib with each selective internal radiation therapy, sorafenib also dominated all selective internal radiation therapies. Limitations The existing evidence cannot provide decision-makers with clear guidance on the comparative effectiveness of treatments in early- and intermediate-stage hepatocellular carcinoma or on the efficacy of TheraSphere or QuiremSpheres. Conclusions In the advanced-stage hepatocellular carcinoma population, two large randomised trials have shown that SIR-Spheres have similar clinical effectiveness to sorafenib. None of the selective internal radiation therapies was cost-effective, being more costly and less effective than lenvatinib, both at list price and with Patient Access Scheme discounts. Future work Future studies may wish to include early- and intermediate-stage hepatocellular carcinoma patients and the low tumour burden/albumin–bilirubin 1 subgroup of advanced-stage patients. Future high-quality studies evaluating alternative selective internal radiation therapies would be beneficial. Study registration This study is registered as PROSPERO CRD42019128383. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 24, No. 48. See the NIHR Journals Library website for further project information." @default.
• W3089367981 created "2020-10-08" @default.
• W3089367981 creator A5008351749 @default.
• W3089367981 creator A5017661377 @default.
• W3089367981 creator A5041328492 @default.
• W3089367981 creator A5073128022 @default.
• W3089367981 creator A5077862180 @default.
• W3089367981 creator A5081742608 @default.
• W3089367981 creator A5087069990 @default.
• W3089367981 creator A5090867877 @default.
• W3089367981 creator A5051570653 @default.
• W3089367981 date "2020-09-01" @default.
• W3089367981 modified "2023-10-12" @default.
• W3089367981 title "Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation" @default.
• W3089367981 cites W1574346845 @default.
• W3089367981 cites W1585533706 @default.
• W3089367981 cites W1851007124 @default.
• W3089367981 cites W1886706265 @default.
• W3089367981 cites W1938013254 @default.
• W3089367981 cites W1969405220 @default.
• W3089367981 cites W1970908877 @default.
• W3089367981 cites W1971380142 @default.
• W3089367981 cites W1971837077 @default.
• W3089367981 cites W1972932269 @default.
• W3089367981 cites W1973617654 @default.
• W3089367981 cites W1982147291 @default.
• W3089367981 cites W1982153769 @default.
• W3089367981 cites W1982200516 @default.
• W3089367981 cites W1982967337 @default.
• W3089367981 cites W1985013718 @default.
• W3089367981 cites W1988816608 @default.
• W3089367981 cites W1995731140 @default.
• W3089367981 cites W1997444312 @default.
• W3089367981 cites W1998417832 @default.
• W3089367981 cites W1999757855 @default.
• W3089367981 cites W2000724394 @default.
• W3089367981 cites W2008423320 @default.
• W3089367981 cites W2012394155 @default.
• W3089367981 cites W2016199951 @default.
• W3089367981 cites W2017938115 @default.
• W3089367981 cites W2019607817 @default.
• W3089367981 cites W2020134441 @default.
• W3089367981 cites W2022122638 @default.
• W3089367981 cites W2022384547 @default.
• W3089367981 cites W2028319026 @default.
• W3089367981 cites W2032224733 @default.
• W3089367981 cites W2032422795 @default.
• W3089367981 cites W2034697000 @default.
• W3089367981 cites W2036304264 @default.
• W3089367981 cites W2050344385 @default.
• W3089367981 cites W2058544933 @default.
• W3089367981 cites W2060513754 @default.
• W3089367981 cites W2066593706 @default.
• W3089367981 cites W2074242143 @default.
• W3089367981 cites W2076668534 @default.
• W3089367981 cites W2077014377 @default.
• W3089367981 cites W2079169996 @default.
• W3089367981 cites W2079516678 @default.
• W3089367981 cites W2079719240 @default.
• W3089367981 cites W2085200083 @default.
• W3089367981 cites W2085246569 @default.
• W3089367981 cites W2085685769 @default.
• W3089367981 cites W2088455745 @default.
• W3089367981 cites W2092759077 @default.
• W3089367981 cites W2098321555 @default.
• W3089367981 cites W2099718495 @default.
• W3089367981 cites W2100770509 @default.
• W3089367981 cites W2100930626 @default.
• W3089367981 cites W2103742396 @default.
• W3089367981 cites W2104274330 @default.
• W3089367981 cites W2113144077 @default.
• W3089367981 cites W2125763116 @default.
• W3089367981 cites W2128125049 @default.
• W3089367981 cites W2133883825 @default.
• W3089367981 cites W2134338345 @default.
• W3089367981 cites W2134791910 @default.
• W3089367981 cites W2136984843 @default.
• W3089367981 cites W2142426633 @default.
• W3089367981 cites W2147562109 @default.
• W3089367981 cites W2155059637 @default.
• W3089367981 cites W2156098321 @default.
• W3089367981 cites W2167501278 @default.
• W3089367981 cites W2169361541 @default.
• W3089367981 cites W2169630868 @default.
• W3089367981 cites W2271921187 @default.
• W3089367981 cites W2277004004 @default.
• W3089367981 cites W2279273926 @default.
• W3089367981 cites W2280049167 @default.
• W3089367981 cites W2309528973 @default.
• W3089367981 cites W2315027248 @default.
• W3089367981 cites W2315239834 @default.
• W3089367981 cites W2318607209 @default.
• W3089367981 cites W2324184406 @default.
• W3089367981 cites W2328890478 @default.
• W3089367981 cites W2330155213 @default.
• W3089367981 cites W2346328604 @default.
• W3089367981 cites W2419462438 @default.
• W3089367981 cites W2509930573 @default.

• next